Atria Wealth Solutions’s Galectin Therapeutics GALT Stock Holding History

Atria Wealth Solutions’s Portfolio GALT Stock Details GALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-186,000	Closed	-$227K	–	1627
2025 Q1	$227K	Sell	186,000 -21,100	-10%	-$29.6K	﹤0.01%	1651
2024 Q4	$267K	Hold	207,100	–	–	﹤0.01%	1629
2024 Q3	$570K	Sell	207,100 -6,700	-3%	-$16.5K	0.01%	1182
2024 Q2	$483K	Sell	213,800 -1,000	-0.5%	-$3.04K	0.01%	1256
2024 Q1	$513K	Sell	214,800 -35,000	-14%	-$66.2K	0.01%	1247
2023 Q4	$415K	Sell	249,800 -10,000	-4%	-$19.4K	0.01%	1310
2023 Q3	$499K	Sell	259,800 -1,000	-0.4%	-$1.65K	0.01%	1128
2023 Q2	$376K	Sell	260,800 -2,500	-0.9%	-$4.24K	0.01%	1307
2023 Q1	$553K	Sell	263,300 -7,400	-3%	-$11.9K	0.01%	1073
2022 Q4	$306K	Sell	270,700 -8,000	-3%	-$10.7K	﹤0.01%	1349
2022 Q3	$454K	Sell	278,700 -3,000	-1%	-$5.61K	0.01%	1074
2022 Q2	$369K	Sell	281,700 -4,000	-1%	-$5.75K	0.01%	1115
2022 Q1	$460K	Buy	+285,700	New	+$553K	0.01%	1109

Other funds holding GALT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

WANY

Wealthspire Advisors (New York) New York $12.7B AUM 17.31% 1-Year Est. Return

GWM

Geneos Wealth Management Englewood, Colorado $4.31B AUM 18.36% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Atria Wealth Solutions's GALT Position: Q2 2025 in Review

Atria Wealth Solutions sold out of Galectin Therapeutics (GALT) in Q2 2025, closing a stake of 186,000 shares — an estimated $227K sold.

Atria Wealth Solutions first reported a position in GALT in Q1 2022 and held it in 13 quarters. The position peaked at $570K in Q3 2024. 86 funds tracked by Wall St. Rank hold GALT as of Q2 2025.

Atria Wealth Solutions reported no remaining Galectin Therapeutics position as of Q2 2025 after selling out during the quarter.
Atria Wealth Solutions sold 186,000 Galectin Therapeutics shares in Q2 2025, an estimated $227K.
Atria Wealth Solutions first reported a position in Galectin Therapeutics in Q1 2022 and held it in 13 quarters.
Atria Wealth Solutions's Galectin Therapeutics position peaked at $570K in Q3 2024.
86 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2025.

Based on Atria Wealth Solutions's 13F filing for Q2 2025, filed 25 Jul 2025.